7.38

1.51% 0.11

After Hours: 7.33 -0.05 -0.68%

Instil Bio Inc (TIL)

Overview News Price History Option Chain Financials Discussions Forecast

Instil Bio Inc stock is traded at $7.38, with a volume of 13,523. It is up +1.51% in the last 24 hours and down -5.57% over the past month. Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Previous Close:

$7.27

Open:

$7.3

24h Volume:

13,523

Relative Volume:

0.76

Market Cap:

$50.05M

Revenue:

Net Income/Loss:

$-71.37M

P/E Ratio:

-0.6847

EPS:

-10.7782

Net Cash Flow:

$-46.62M

1W Performance:

-0.40%

1M Performance:

-5.57%

6M Performance:

-7.63%

1Y Performance:

-73.87%

1-Day Range:

$7.30

$7.4999

1-Week Range:

$7.2601

$7.50

52-Week Range:

$5.67

$33.83

Instil Bio Inc Stock (TIL) Company Profile

Name

Instil Bio Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(972) 499-3350

Address

3963 MAPLE AVENUE, DALLAS

Employee

Twitter

Next Earnings Date

2026-08-12

Latest SEC Filings

TIL's Discussions on Twitter

Compare TIL vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TIL Instil Bio Inc	7.38	50.73M	0	-71.37M	-46.62M	-10.78
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Instil Bio Inc Stock (TIL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-07-26	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-06-26	Downgrade	Robert W. Baird	Outperform → Neutral
Jan-07-25	Upgrade	Jefferies	Hold → Buy
Nov-04-24	Initiated	JMP Securities	Mkt Perform
Apr-12-24	Downgrade	Jefferies	Buy → Hold
Nov-01-22	Downgrade	Cowen	Outperform → Market Perform
Nov-01-22	Downgrade	Truist	Buy → Hold
Aug-13-21	Initiated	Robert W. Baird	Outperform
Apr-13-21	Initiated	Cowen	Outperform
Apr-13-21	Initiated	Morgan Stanley	Equal-Weight
Apr-13-21	Initiated	Truist	Buy

View All

Instil Bio Inc Stock (TIL) Latest News

Aug 14, 2026

Why (TIL) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Aug 14, 2026

Aug 13, 2026

Instil Bio, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 13, 2026

Form 8K Instil Bio Inc For: 13 August By Investing.com - Investing.com Nigeria

Aug 13, 2026

Instil Bio Reports Second Quarter 2026 Financial Results - Intellectia AI

Aug 13, 2026

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times

Aug 13, 2026

Instil Bio Reports $4.3 Million Second-Quarter 2026 Net Loss - Quiver Quantitative

Aug 13, 2026

Instil Bio, Inc. 2026: Revenue ($4.35M), Net income ($4.3M), EPS ($0.63) — 10-Q Summary - TradingView

Aug 13, 2026

Instil Bio reports Q2 2026 net loss $4.3M, cash and marketable securities $69.9M - TradingView

Aug 13, 2026

Instil Bio (TIL) slashes R&D spend and leans on Tarzana lease income in Q2 2026 - Stock Titan

Aug 13, 2026

Instil Bio expects $69.9M cash to fund plan beyond 2027 - Stock Titan

Aug 13, 2026

Instil Bio (Nasdaq: TIL) trims Q2 2026 loss and extends cash runway - Stock Titan

Aug 13, 2026